Cargando…
OX40‐targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice
Despite promising preclinical and clinical data demonstrating that immune agonist antibody immunotherapies (IAAs) such as αOX40 induce strong antitumor immune responses, clinical translation has been significantly hampered by the propensity of some IAAs to induce dose‐limiting and sometimes life‐thr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493970/ https://www.ncbi.nlm.nih.gov/pubmed/34632317 http://dx.doi.org/10.1096/fba.2021-00039 |